PREDETERMINATION BY INFECTION AND BY VACCINATION OF ANTIBODY RESPONSE TO INFLUENZA VIRUS VACCINES by Davenport, Fred M. & Hennessy, Albert V.
PREDETERMINATION  BY INFECTION  AND BY VACCINATION OF 
ANTIBODY RESPONSE TO INFLUENZA VIRUS VACCINES* 
BY  FRED  M.  DAVENPORT,  M.D.,  AtOP ALBERT  V.  HENNESSY,  M.D. 
WY£E THE TECHNICAL  ASSISTANCE  OF PHYLI2S H.  FABISCF[ 
(From the Department of Epidemiology and Virus Laboratory, School of Public Health, 
University  of  Michigan,  Ann  Arbor) 
(Received for publication,  August 2,  1957) 
Susceptibility to influenza is greatest in childhood, and tends to decline progressively 
with age (1-3). Recent studies have shown a striking correlation between an increase 
in resistance to influenza and the acquisition with age of broadly reacting antibody 
due to repeated exposures to many antigenic variants of influenza virus (4-7). Viruses 
of influenza A  may be divided serologically into three antigenic families; swine,  A, 
and A-prime: In each family a  characteristic set of components is dominant. Minor 
antigenic components are widely shared between them (8). Viruses of each family have 
been prevalent during successive periods of time, and as a result, different age segments 
of the population have had different amounts of experience with each family of viruses; 
they have different antibody patterns, and different states of immunity (5, 6, 8). For 
example, the antibody pattern of children consists principally of A-prime antibodies. 
The attack rate is at all times highest during this period of life. From age 12 to 29, the 
antibody pattern is broader, comprising antibodies to A as well as the A-prime strains. 
The incidence of influenza is considerably lower at these ages. The antibody pattern 
of persons over 30 is the broadest, and is composed of swine, A, and A-prime antibodies. 
The incidence of influenza is lowest in this age category. 
To induce at all ages a  broad composite of antibody which resembles  that of the 
older segments of the population,  whose antigenic experience is greatest and whose 
susceptibility is least, has become a goal for artificial immunization. Previous studies 
with  monovalent aqueous  influenza  virus  vaccines have  emphasized  the  dominant 
effects  of the major antigens of strains of past infection upon the range of antibody 
response to vaccination (9).  Thus, while  antibody to strains previously encountered 
was reinforced in all age groups regardless of the antigenic composition of the vaccine 
administered, children generally did not develop antibodies to swine or A strains unless 
given virus of that character. Persons of military recruit age generally did not develop 
* These studies were conducted under the auspices of the Commission on Influenza, Armed 
Forces  Epidemiological Board,  and were supported  by the Office of the Surgeon General, 
Department of the Army, Washington, D. C. They were presented in part at the 29th annual 
meeting of the Central  Society for Clinical Research at Chicago on November 9, 1956. 
1  Recent  evidence suggests that viruses belonging to a fourth antigenic family of strains 
have appeared from the Far East.  (17) 
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swine antibodies unless given swine vaccine. Persons over 30 developed only very low 
levels of A-prime antibodies unless A-prime vaccines were used. Consequently, compo- 
site or broadly reacting antibody could not be induced at all ages by any of the mono- 
valent aqueous vaccines tested. 
The purpose of the present study was to determine how to induce by vac- 
cination high levels of composite antibody in persons of all ages, despite dif- 
ferences in their prior antigenic experiences. The range of antibody response in 
children,  recruits,  and  persons  over  30,  following  a  single  inoculation of 
monovalent adjuvant, polyvalent adjuvant, or  polyvalent aqueous influenza 
virus was studied. These results prompted investigations carried out in children 
and in persons over 30 using multiple doses of vaccine. It was demonstrated 
that  vaccination, like infection, can predetermine the  range of  antibody re- 
sponse to subsequent antigenic stimulation. In consequence, it becomes feasible 
to obtain high levels of composite antibody, despite differences in age and past 
experiences, if suitable preparations and schedules are employed. 
Materials and Methods 
Vacdnes.--All  vaccines used were prepared  on request  by commerciai pharmaceutical 
firms. Centrifugation was used for concentration and purification of virus intended for adju- 
vant vaccines, adsorption and elution from chicken red blood cells for virus intended  for 
aqueous vaccines. In either case, virus suspensions were then inactivated with formalin (1: 
4,000), and merthiolate (1:10,000) was added as a preservative. Adjuvant  vaccines were made, 
by emulsifying a volume of virus concentrate containing 4 mg. per ml. of aluminum  phosphate 
with an equal volume of a  mixture containing 9 parts of light medicinal mineral oil (dmkeol 
6-VR) and one part emulsifier (purified arlacel A). A volume of 0.25 ml. of adjuvant vaccine 
was given intramuscularly in the posterior belly of the triceps muscle. Aqueous vaccines were 
administered subcutaneously in 1.0 ml. doses. 
Subjeas.--Antibody  response to these experimental vaccines was studied in children aged 
4 to 10 (median  = 7), military recruits aged 17 to 28 (median  = 18), and in  adults  30 or more years 
of age (median  =47). Thechildrenandpersons over 30 years of age were inmates of state mental 
institutions.  Military recruits were airmen stationed at Sampson Air Force Base, Geneva, 
New York, for basic training.  2 
Immunization  and Bleeding Schedules.--In  groups of 25,  children, recruits, and persons 
over 30 were bled and vaccinated. A second bleeding was obtained 2 weeks after aqueous vac- 
cine and 6 weeks after adjuvant vaccine. 
Treatment of Sera.--Serum was promptly separated from each blood sample, and merthio- 
late (1:1,000) was added to yield a final concentration of 1:10,000. For certain experiments, 
pools of sera derived from samples obtained before and after each vaccination were made by 
combining appropriate aliquots. Sera were stored at 4°C., and heated at 56°C. for 30 minutes 
prior to use. 
Hemagglutination-lnhibition Titrations.--The  hemagglutination-inhibition  titers  of  sera 
were determined by a pattern method with 4 units of virus and 0.5 per cent chicken erythro- 
cytes suspended in saline (10). Antibody titers are expressed as the reciprocal of final dilutions 
of sera. 
2  It is a pleasure to acknowledge the assistance of Dr. Harold B. Houser, Director, and of 
the officers and enlisted men of the Laboratory on Housing and Illness, Sampson Air Force 
Base. F. M.  DAVENPORT  AND A. V. HENNESSY  837 
Virus.--Strains  of influenza virus used for vaccination and for antibody determinations 
were chosen from the collection of the Strain Study Center, Commission on Influenza, School 
of Public Health, Ann Arbor. They were: swine No.  1976  (1931),  PR8  (A-1934), FM1  (A'- 
1947),  Cuppett (A'-1950), PR301  (A'-1954), and Malaya 302 (A'-1954). 
Solutio~.--Saline  refers to 0.15 ~  NaCI buffered at pH 7.2 with 0.01  M phosphate. 
EXPERIMENTAL 
Antibody  Response in  Three Age Groups to Monovalenl Adjuvant  Influen~.a 
Virus Vaccines.--It  has been demonstrated that antibody response to adjuvant 
influenza virus vaccines tends to be broader as well as higher than to aqueous 
vaccines  (11). However,  the influence of differences in the prior antigenic ex- 
periences  of persons  of different ages  upon  antibody response  to adjuvant 
AGE  /4-10 
VACCINES  16"~84~ 
4,o~ 
SWINE  1.024  ~ 
PR8  I  I  " 
VM I 
SWINE  (1931)  PR8 (1934) 
17-26  >30  4-10  17-26  >30 
++ 
FMI (1947) 
4-10  17-2($  >30 
MALAYA (1954) 
4-10  17-26  >30 
FIG.  1.  Antibody response  to  monovalent adjuvant influenza virus vaccine in children, 
recruits, and persons over 30 years of age. 
vaccines has not been systematically investigated.  It seemed important, there- 
fore,  to  determine  whether  the  superior  immunizing potency of  adjuvant 
vaccines would invoke a composite of antibodies at all ages, even though a single 
strain was used in the vaccine. For this purpose, groups of 25 children, military 
recruits,  or persons over 30 years of age were given monovalent adjuvant vac- 
cine  containing 250  CCA  (chicken  cell agglutinating) units of either swine, 
PRS, FM1, or Malaya virus. The results of antibody determinations measured 
by hemagglutination inhibition in pools of sera obtained from each age group 
before and after vaccination are reproduced in Fig. 1 as paired bar graphs. The 
first  member of each  pair represents  pre-vaccination,  and the second,  post- 
vaccination levels of antibody. Antibody levels measured with the strain used 
for vaccination (homologous) are shown as open bars, while hatched bars repre- 
sent amounts of antibody measured with heterologous viruses. 838  INFLUENZA VIRUS VACCINES 
Swi~  Vorcine.--Swine  influenza virus vaccine  induced high post-vaccina- 
tion  antibody levels  to  swine virus  in  each  of the  three  age  groups.  The 
highest was found in persons over 30 who alone showed swine antibody before 
vaccination,  and who are believed to have been exposed to swinedike strains 
during their childhood (4, 5). 
Swine virus vaccine  caused  a  remarkable  increase  in antibody to PR8  in 
military recruits. The same vaccine induced little antibody to PR8 in children, 
and only a moderate increase in persons over 30. When antibody determinations 
were carried out with the pairs of sera that had been pooled from each of the 
three age groups,  it was found that only 16 per cent of the children  showed 
an antibody increase to PR8 after vaccination with adjuvant swine vaccine. 
In contrast, all the recruits  and 80 per cent of the persons over 30 showed a 
rise in PR8 antibodies after adjuvant swine vaccine. These  serologic findings 
correlate nicely with what is known of the period of prevalence of influenza A 
and of the age-specific attack rate of that illness. Thus, most children aged 4 
to 10 who were born  after the last wide-spread prevalence  of influenza A in 
1943, show no antibody increase to PR8 after vaccination with swine virus. 
The few children in whom antibody increase was observed are believed to have 
been infected previously with A-like strains. A limited distribution since 1943 of 
the major antigens of the viruses of influenza A has recently been postulated 
and discussed (7). Persons now of military recruit age were children during the 
period of prevalence of influenza A, and the attack rate of influenza A has been 
shown to be highest in the first decade.  Persons  now over 30 were children 
during the period of prevalence of influenza caused presumably by swine-like 
strains,  and these  persons were exposed secondarily  to influenza A probably 
while in their "teens" or "twenties." At these periods of life, the age-specific 
attack rate of influenza A ordinarily has declined from its maximum. Hence, the 
results obtained indicate that swine virus adjuvant vaccine  does not induce 
antibody to PR8 unless previous infection with influenza A has oriented anti- 
body-forming mechanisms to respond in that manner. 
Adjuvant swine vaccine  reinforced  antibody to  FM1  in  children  and  in 
recruits  to approximately the same extent. The post-vaccination  titer to FM1 
in persons over 30 was lower, even though the pre-vaccination  level  approxi- 
mated that of the younger age groups.  Antibody to Malaya strain after ad- 
juvant swine virus vaccine decreased progressively with the age of the group 
vaccinated. 
These serologic findings can be explained by correlating information on the 
time of appearance  of influenza A-prime, the age-specific attack rate of that 
illness, and the occurrence of antigenic variation among strains of the A-prime 
family of influenza virus.  For example,  the data available  indicate that the 
attack rate of influenza A-prime is highest in childhood and declines sharply 
thereafter (3,  7). The children studied in this report were all born during the F. M.  DAVENPORT AND A. V. HENNESS¥  839 
period of prevalence of influenza  A-prime,  and many of the recruits (medium 
age: 18) were in the first decade of llfe when influenza A-prime was first encoun- 
tered in 1947. On the other hand, persons now aged 30 or more were at least 
20 when influenza  A-prime  appeared. It seems likely,  therefore, that many of 
the older children  and the younger recruits had comparable exposures with the 
early strains of influenza  A-prime,  of which FM1 is a prototype, while persons 
over 30 were less intensely affected by virus of that antigenic character. Such 
inferences  are in accord with the observation that antibody response to FM1 
was the same in children  and recruits but less in persons over 30.  Since  the 
appearance of influenza  A-prime,  persons in each of the groups studied have 
become older,  and concurrently, shifting  in antigenic composition of A-prime 
strains of influenza  virus has occurred. Therefore, because the attack rate of 
influenza  A-prime declines  after childhood,  it follows that  children  have had 
the greatest experience  with recent strains of influenza  A-prime,  recruits less, 
and persons over 30 least. The post-vaccination levels  of antibody measured 
in each age group with the Malaya strain of 1954 are in agreement with these 
considerations.  It seems quite dear, especially in view of the consistently low 
levels of post-vaccination A-prime antibody found in persons over 30 that ad- 
juvant  swine  virus vaccine  did  not  broaden  antibody  response  to  A-prime 
strains except as can be explained by previous infection. 
PR8  Vaccine.--PR8 adjuvant vaccine induced high  post-vaccination anti- 
body titers  to swine  influenza  virus only in persons over 30.  The low post- 
vaccination antibody level to swine virus present in pools of sera obtained from 
children  and recruits was shown to be due to antibody increase  in but a small 
proportion of the individuals of each group,  and  this proportion was similar 
to that  found after aqueous PR8 vaccine  (9).  Evidence suggesting  a  limited 
distribution of the major antigens of swine-like strains in recent years has been 
presented previously (7). Clearly children  and military recruits have had rela- 
tively minimal  prior  antigenic  experience  with  the  major  antigens  of swine 
influenza  virus and vaccination with adjuvant PR8  vaccine did not broaden 
antibody response  as measured with swine virus beyond limits determined by 
the effects of previous exposures. 
Antibody response  to the homologous strain (PR8) was greatest in military 
recruits,  less  in persons  over 30,  and  least  in  children.  The  explanation  for 
these findings is again offered that persons of military recruit age have had the 
greatest, persons over 30 less, and children  the least previous antigenic experi- 
ence with the major antigens of influenza  A strains. 
The pattern  of antibody increase  to FM1  and Malaya strains,  after PR8 
adjuvant vaccine, was like  that observed after swine virus adjuvant vaccine, 
although post-vaccination levels  were somewhat lower.  The interpretation  of 
the antibody responses  is essentially the same offered to explain  the findings 
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FMI Vaccine.--FM1  adjuvant vaccine induced antibody responses to swine 
influenza virus in the three age groups much like that seen after vaccination 
with PR8. Antibody to PR8 in response to FM1 adjuvant vaccine was absent 
in  children and moderate,  though equal,  in  recruits and in persons over 30. 
Again  the failure of monovalent adjuvant  vaccines to broaden antibody re- 
sponse in children  to swine or PR8,  and in recruits to swine virus is noted. 
FM1 vaccine induced high levels of homologous antibody in each of the three 
age groups studied.  Nevertheless,  the final  titer achieved by the  oldest  age 
group was the lowest. Antibody response as measured with Malaya virus was 
of the same pattern. 
The results of these experiments are in  remarkable  agreement with  those 
observed previously with  aqueous  monovalent  influenza  virus  vaccines  (9). 
They demonstrate that heterologous antibody responses to monovalent adju- 
vant vaccines do not broaden beyond the confines predetermined by the major 
antigens of past  infections. Hence, composite antibody could not be induced 
at all ages by vaccines containing a  single strain of virus of the nature here 
employed. 
Antibody Response to Polyvalent Aqueous and Adjuvant Vaccines in the Same 
Three Age Groups.--Recognizing the limitations in antibody response to mono- 
valent vaccines, it seemed logical to formulate and to test polyvalent vaccines, 
to ascertain whether preparations containing representative strains of swine, 
A, and A-prime virus were capable of inducing a  composite of antibodies ir- 
respective of age and differences in prior exposures. To measure the breadth 
and  height  of antibody response  to  a  polyvalent aqueous  and  a  polyvalent 
adjuvant vaccine the following experiment was carried out. 
Groups comprising 25 children, recruits, or persons over 30, respectively,  were bled, vac- 
cinated, and bled again. The aqueous vaccine  given to children  and persons over 30 contained 
equal parts of swine, PR8, FM1, and Cuppett strains in a total concentration of 750 CCA 
units per ml.; that given to recruits contained one part each of swine, PR8, and PR301 in a 
final concentration of 800 CCA units per mL The adjuvant vaccine given to all three age 
groups contained equal parts of swine, PR8, and PR301 strains in a final concentration  of 200 
CCA units per 0.25 ml. Table I presents the geometric  mean HI antibody titers determined 
with swine, PR8, FM1, and Malaya 302 strains in pairs of sera obtained before and after 
vaccination. 
Children.--In  children,  while antibodies to all three families of virus were 
evoked by both  types of vaccine, post-vaccination antibody levels to  swine 
and PR8 were relatively low. The antibody response to the two vaccines ap- 
peared equal except that the level of FM1 antibody was higher after aqueous 
vaccine. This difference may be related to the fact that FM1  was contained 
in the aqueous vaccine, and  that  the antibody response of children tends to 
be strain-specific. The pattern of antibody response in these children demon- 
strates  again  that  their exposures were largely limited  to  influenza A-prime 
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Recruits.--In  recruits,  post-vaccination  antibody  levels  to  the  four  test 
strains were higher after adjuvant than after aqueous vaccine. In either case, 
the highest titer was found with PR8. With adjuvant vaccine, the response to 
A-prime strains was also broader. As a  result,  the height of the titers of the 
composite of antibodies against influenza was more uniform. Aqueous vaccine 
induced in recruits low levels of swine antibody similar to those found in chil- 
dren after either vaccine. Post-vaccination A-prime antibody titers in recruits 
given aqueous  vaccine  were  slightly lower  than  those of children  receiving 
aqueous vaccine, but the titers after adjuvant vaccine were considerably higher. 
The  antibody response  to  swine, A,  and A-prime  strains seen in  recruits is 
ordered in magnitude in accordance with the amount of exposure persons of 
this age have had with each of the families of virus. 
Persons over 30.--In persons over 30, post-vaccination antibody levels after 
either vaccine were much higher against swine virus than in the younger age 
TABLE  I 
Comparison o/Antibody Response in Three Age Groups to Polyvalent Aqueo.,~s and Adjuvant 
Influenza Virus Vaccine 
Age 
I  AvqcUce°mUe  s 
Childrea 
Recruits  ]  <32/79 
Persons  [  282/1,638 
>30 yrs.[ 
Antibody titer to strain 
Swine  PR8  FM1  Malaya 
Adjuvant 
vaccine 
<32/64 
<32/256 
179/1,843 
Aqueous  [  Adjuvant 
vaccine  vaccine 
<32/77  <32/61 
128/1,434  I  83/4,096 
92/922  !  48/717 
Aqu~?~  ] A~:ian~t 
58/I,22--------~  35/41--------~ 
109/768  ] 154/2,867 
961460  38/333 
Adjuvant]  Aqueous  vneein_____~  vaccin____~e 
45/410  32/410 
54/256  [  128/2,862 
<32/90  }<32/192 
I 
* Geometric mean pre- and  post-vaccination HI antibody  titers. 
groups. PR8 antibody levels were intermediate between those found after vac- 
cination in recruits and in children. Post-vaccination A-prime antibody levels 
were the lowest of the three age groups studied, and it is noted that before 
vaccination this older group had little or no antibody to the recent Malaya 
strain.  They behave  with respect  to  Malaya antibody as  children  do  when 
given the swine and PR8 strains. There was no real difference in response to 
aqueous and adjuvant preparations. Clearly, the pattern of antibody response 
of persons over 30 reflects the gradation in amounts of experience this age group 
has had with swine, A, and A-prime viruses. 
These findings indicate that although a  composite of antibody to swine, A, 
and A-prime viruses can be stimulated by polyvalent aqueous and polyvalent 
adjuvant vaccines, the magnitude of the antibody increases observed in each 
age group was proportionate to the prior antigenic exposure of each cohort as 
reflected in  initial antibody titers.  Hence,  the  most noticeable  effect of the 
polyvalent vaccines used was to provide a  "booster" stimulus. Nevertheless, 
the primary vaccination may establish a foundation of antibody against strains 842  INFLUENZA VIRUS VACCINES 
not previously encountered,  as  witnessed  by a  comparison of pre- and  post- 
vaccination antibody levels. 
Predetermination of Antibody Response by Vaccination.--Since single doses of 
aqueous or adjuvant monovalent vaccine, and single doses of aqueous or adju- 
vant polyvalent vaccine had failed to induce high levels of composite antibody 
at all  ages,  the next experimental  approach was to learn whether vaccination 
could meet  the deficit in natural  antigenic  experience  that  characterizes  each 
of the age groups studied. As a  beginning, it was decided to ascertain whether 
vaccination with  strains  prevalent  before their  birth  could persistently  orient 
the  antibody response  of children  to revaccination  with  strains  antigenically 
like those of recent circulation.  By such an experiment,  it was also recognized 
that a  direct test  could  be  derived  of the  thesis  that  antibody stimulated  by 
TABLE II 
Predaermination by Vaccination of Antibody Response to Subsequent Inoculation 
Vaccine 
Malaya adjuvant 
Malaya adjuvant 
Antibody titer to strain 
Swine  [  PR8  [  FM1  [  Malaya 
77"/461" 
<32/<32 
Previously vaccinated children (17) 
35/115  [  1,638/10,650 
Unvaccinated children (24) 
<32/<32[  115/1,946 
461/9,830 
115/3,482 
* Geometric mean HI antibody titer before and after vaccination. 
exposure  to heterologous strains  of influenza  virus is persistently  oriented  by 
the major antigens formerly encountered. 
Antibody Orientation  to Primary  Vaccine.- 
For this purpose, a group of 17 children was available who had been vaccinated 1 year pre- 
viously with aqueous suspensions of swine and PR8 viruses. Because of the design of experi- 
ments reported  previously, these children had received in sequence at 2 week intervals  1.0 
ml. subcutaneously of monovalent aqueous influenza virus vaccines containing swine, Cup- 
pett, PR8, and FMI strains, respectively. The concentration of virus in each vaccine was 750 
CCA units per ml. (9). 
To determine the effects of the previous vaccinations upon antibody response, 0.25 ml. of 
adjuvant vaccine, containing 250 CCA units of Malaya 302, was given intramuscularly.  As a 
control, Malaya adjuvant vaccine was given to 24 children of the same age who had not been 
vaccinated  previously. HI antibody levels determined  with swine, PR8, FM1, and Malaya 
strains  of virus  in sera obtained  before and 6 weeks after vaccination  with the adjuvant 
preparation  are shown in Table II. 
The sera of the children vaccinated one year previously with swine, Cuppett, 
PRS, and FM1 aqueous vaccine still contained low levels of antibody to swine, Y. M.  DAVENPORT  AND V.  A. HENNESS¥  843 
and PR8, but high levels to FM1 and Malaya strains. Vaccination with adju- 
vant vaccine containing Malaya virus caused a  marked reinforcement of anti- 
body to swine virus, a  significant but less dramatic reinforcement of antibody 
to PR8 and, despite high pre-vaceination levels, an extensive increase in anti- 
body  to  FM1  and  Malaya.  Vaccination  with  adjuvant  vaccine  containing 
Malaya virus did not increase antibody to swine or PR8 strain in the control 
group of children. Pronounced reinforcement of A-prime antibody levels, how- 
ever, did occur. These results clearly demonstrate that prior contact with the 
major antigens of swine and PR8 given by vaccination has oriented antibody 
response so that subsequent vaccination with Malaya virus, which apparently 
contains swine and PR8-1ike antigens as minor components, results in reinforce- 
ment of antibody to swine and PR8. 
TABLE  ILI 
Additi¢e Effects of Revaccination u~on Antibody Foundation Constructed by Primary Vaccine 
Vaccine 
Polyvalent aque- 
ous 
Malaya adju- 
vant 
FM1 adjuvant 
PR8 adjuvant 
PR8 adjuvant 
Date 
Dec. 1954 
Feb. 1956 
Aug. 1956 
:an. 1957 
Previously un- 
vaccinated 
children 
Swine 
<32*/64* 
<32/243 
192/922 
614/1,951 
<32/32 
Antibody 'riter to strain 
PR8  FMI 
<32/77  48/666 
<32/48  128/7,963 
42/64  6,144/26,214 
58/9,011 12,288/15,565 
~32/384  61/666 
Malaya 
35/230 
68/6,963 
7,373/24,57~ 
10,650/13,92~ 
<32/256 
* Geometric mean HI antibody titer before and after vaccination. 
Persistence of Antibody  Foundation Laid Down by the  Primary  Vaccine.- 
The  orienting  effect  produced  by  vaccination  was  found  to  be  remarkably 
persistent. 
A second group of 15 children was studied who had receivedin December, 1954, a polyvalent 
aqueous vaccine containing swine, PR8, FMI, and Cuppett strains in a concentration of 750 
CCA units per ml. In February, 1956, these children were revaccinated intramuscularly with 
an adjuvant vaccine containing 250 CCA units of Malaya virus; in August, 1956, they were 
given an adjuvant preparation containing 250 CCA units of FM1 virus, and in January, 1957, 
they received an adjuvant  PR8 vaccine containing 250 CCA units per dose. Bloods were 
obtained before each vaccination and 2 weeks  after aqueous or 6 weeks  after adjuvant vaccines 
were given. The results of antibody determinations with swine, PR8, FM1, and Malaya virus 
are shown in Table 11I. 
The antibody response to polyvalent aqueous vaccine recorded in these tests 
is similar to that shown in Table I  since these 15 children were a  part of that 844  INFLUENZA  VIRUS  VACCINES 
original group of 25. Antibody titers measured in sera obtained before vaccina- 
tion with Malaya adjuvant vaccine demonstrate the decline in the ensuing 14 
months of antibody levels from those observed 2 weeks after vaccination  with 
polyvalent aqueous vaccine. The results shown 6 weeks after vaccination with 
Malaya adjuvant vaccine may not he attributable solely to the effects of stimu- 
lation by revaccination  since simultaneously an epidemic of influenza A-prime 
occurred in the institution where the children were cared for. However,  pools 
of serum from an unvaccinated control group of children bled at the same inter- 
vals showed antibody increase only to A-prime strains and it has been demon- 
strated (cf.  Table II) that Malaya adjuvant vaccine does not ordinarily cause 
antibody increase in children to swine or PR8 strains.  Therefore,  for conven- 
ience in presentation, the antibody response of these  children in this interval 
will be  spoken  of as antibody response  to revaccination,  even  though it  is 
realized that an indeterminate, though probably minor amount of the antibody 
increases observed, may have resulted from infection. With these reservations, 
vaccination with Malaya adjuvant vaccine was followed by a  sharp  increase 
in antibody to swine virus, and a lesser response to PR8. As would be expected 
in children, a marked increase in A-prime antibodies  occurred. 
Six months later, at a time when influenza was not occurring at the institu- 
tion  (August,  1956), these  children  were revaccinated with  FM1  adjuvant. 
An antibody increase to swine virus was again observed and the level attained 
was greater than that found after the previous  vaccinations; it was about 8- 
fold  higher  than  those observed  after either  initial polyvalent vaccine  (of. 
Table I). This result  indicates  a persistence of antibody orientation to swine 
virus for 20 months after the initial vaccination. 
It is noteworthy that antibody increase  to A-prime  strains was  observed 
after each vaccination and that the amounts of antibody produced were large. 
Once again these findings illustrate the phenomenon of reinforcement  by vac- 
cination of antibody to strains of primary infection. 
There was a less efficient orientation of antibody production to PR8 by the 
original  vaccination of the children.  While  both A-prime  adjuvant vaccines 
did cause some enhancement of PR8 antibodies,  the amounts obtained after 
revaccination  were relatively low. Previous  studies have indicated a  greater 
antigenic crossing between  swine and recent A-prime  strains than with PR8 
(9). The comparatively  poor PR8 response may then reflect the relative paucity 
of PR8 antigen in the FM1 and Malaya A-prime strains.  It is also possible 
that when given together swine virus may preempt the antibody-forming sites 
capable of being sensitized through vaccination. 
To determine whether the initial polyvalent vaccine  containing PR8 had 
exerted any significant orientation upon antibody formation to that strain, these 
15  children  were then vaccinated in January, 1957, with an adjuvant mono- 
valent PR8 vaccine. The PR8 antibody had not changed significantly during 
the 5 month interval since vaccination in August,  1956. After revaccination F. M.  DAVENPORT  AND A. V. HENNESS¥  845 
with PR8 strain, antibody measured  with PR8 virus rose to high levels. The 
geometric mean titer of 9011 achieved in these children is in marked contrast 
to that of 384 observed in a group of 25 previously unvaccinated children fol- 
lowing an initial vaccination with the same PR8 adjuvant vaccine. The marked 
difference in the titers achieved in these two groups of children indicates  that 
the PR8 given these 15  children  25 months before in the polyvalent aqueous 
vaccine, had in fact effectively sensitized the PR8 antibody-forming  mechanism 
although it had been less responsive to heterologous stimuli than was the case 
with swine antigen. 
Antibody to swine strain had persisted at a high level since the last vaccina- 
tion 6 months before, and after revaccination  with PR8 was reinforced  to a 
still higher level. This result indicates that once the antibody-forming mecha- 
nism is properly oriented successive vaccinations with related but heterologous 
strains result in progressively  higher  titers. 
Antibody reacting with A-prime strains was very high before revaccination 
and increased to higher levels following vaccination although not to the heights 
noted after vaccination in August with FM1 strain. The observations  suggest 
that the antibody production to those dominant antigens had become so com- 
plete as to be less reactive to an additional stimulus. 
The findings  demonstrate that high levels of composite  antibody can  be 
achieved  and maintained in children  by an initial sensitization  with a  poly- 
valent  aqueous  vaccine,  followed by  successive revaccination  with  selected 
monovalent adjuvant vaccines. In addition, the results afford a striking illus- 
tration of the principle that antibody response to vaccination or infection with 
various  but related strains is oriented by the major antigens of the viruses 
previously  encountered.  Similar experiments  have been  carried out with vac- 
cines made from strains of influenza B and the results are similar (12). 
Influence of Repeated Vaccination with Polyvalent Vaccine upon Antibody 
Response.--In the light of the objective for artificial immunization previously 
stated, that is, to induce at all ages high levels of a broad composite of anti- 
body, the data obtained made it of special interest to ascertain whether high 
levels of composite antibody could be induced in children by giving polyvalent 
influenza virus vaccines in sequence. 
To  test this possibility, there was available a  group of 25 children who had  received a 
polyvalent adjuvant vaccine in July, 1956. These children were revaccinated with polyvalent 
aqueous vaccine in January,  1957.  The polyvalent adjuvant vaccine contained per dose 50 
CCA units each of swine, PRS, and PR301 strains. The polyvalent aqueous vaccine contained 
per ml. 200 CCA units each of the same viruses. The results of hemagglutination inhibition 
antibody determinations made with swine, PR8, FM1, and Malaya strains are represented in 
Table IV as geometric mean titers. 
Children.--The antibody response of these children  to polyvalent adjuvant 
vaccine was somewhat greater to each virus than that of another group given, 
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position  (cf.  Table I). Nevertheless,  the pattern of antibody response is very 
similar in both groups  with the dominant increases to A-prime  strains.  The 
adjuvant vaccine given in the summer of 1956 appears to be a better antigenic 
agent than that given in the fall of 1955. Antibody levels against swine, PR8, 
FM1,  and Malaya strains induced  by the polyvalent adjuvant vaccine  were 
maintained until January, 1957. Antibody increase to aqueous  vaccine given 
7 months later as measured with swine virus, was more than 5-fold, with PR8 
9-fold; antibody increases measured  with FM1 and Malaya strains were less 
than 2-fold. However,  levels of antibody against these strains were already 
high before revaccination.  As a  result of revaccination,  good titers were now 
evident against all test strains; the lowest titer, that of swine virus,  was over 
800. Comparison of antibody levels attained to the same test strains after a 
TABLE IV 
Antibody Response in Children and Persons >30 lo Successive Injections of Polyvalent Influenza 
Virus Vaccine 
Group 
~'hildren 
Persons 
Vaccine 
Polyvalent ad- 
juvant 
Polyvalent 
aqueous 
Polyvalent ad- 
juvant 
Polyvalent 
aqueous 
Date 
July1956 
Jan. 1957 
Sept. 1955 
Jan. 1957 
Swine 
<32"/141" 
154/819 
154/1,843 
1,434/3,072 
Antibody  titer to Strain 
PR8 
<32/154 
230/2,048 I, 536/2,048 
38/512 
358/1,741 
FM1  [  Mahya 
51/1,843  83/2,867 
2,458/3,891 
40/410  32/166 
282/512  122/333 
* Geometric mean HI antibody titer before and after vaccination. 
single vaccination with either  polyvalent adjuvant or  aqueous  vaccine  (cf. 
Table I) demonstrates the serologic advantage of using these two vaccines in 
sequence.  Clearly the revaccinated children  achieved  higher levels of a  com- 
posite of antibodies.  The suggestion is obvious, that after a primary vaccina- 
tion with a good adjuvant vaccine, the aqueous vaccine may then be used after 
an appropriate interval as a booster to induce high levels of antibody to mul- 
tiple strains,  including  those  to which original antigenic  experience is gained 
by vaccination. 
Persons over 30.--A  similar experiment was carried out in a group of 20 per- 
sons over 30 years of age who had received the less potent polyvalent adjuvant 
vaccine in September of 1955 and were revaccinated 17 months later in Febru- 
ary, 1957, with polyvalent aqueous vaccine. The results are shown in the lower 
part of Table IV. Since the 20 persons used in this group were part of the 25 
individuals whose response to adjuvant vaccine is shown in Table I, the initial F.  M.  DAVENPORT  AND A. V.  HENNESSY  847 
response  to vaccination will not be discussed.  It is notable that the antibody 
levels to all strains declined  but slightly in the 17 months after adjuvant vac- 
cination.  Revaccination with polyvalent aqueous vaccine caused a prompt and 
substantial  increase  in antibody to all  test strains.  The increase  in antibody 
was about 2-fold to swine, FM1, and Malaya strains, and 4-fold to PR8. The 
results  are  the  reverse of those  in  children;  here  the  swine  antibody is  the 
dominant one, but firm and good levels of antibody to the strains of secondary 
exposure are well established. Again,  comparison of antibody levels achieved 
after a  single dose of adjuvant  or aqueous polyvalent vaccines  (cf.  Table I) 
with those observed after use of polyvalent vaccines in sequence after a  sub- 
stantial interval, demonstrates the superiority of the antibody response follow- 
ing the latter procedure and the resultant higher  levels of a composite of anti- 
bodies against antigenically representative strains of group A influenza viruses. 
It  is  noteworthy that  the  antibody-orienting  effect of the  first  vaccination 
persisted  in  this experiment for at  least  18 months.  The results of all these 
studies exemplify again  the characteristic  antibody pattern  and responses in 
different segments of the population--differences based upon first experiences 
and conditioned responses. 
The data presented demonstrate that it is possible to obtain high  levels  of 
composite antibody, despite differences  in age and past experience,  if suitable 
preparations and schedules  are employed. It should be pointed out that much 
of the considerations of vaccination against influenza  has been dominated by 
the results of studies of repeated inoculation of adults at short intervals,  i.e. 
weeks, with  limited strain  distribution  and with  the military emphasis on a 
single dose. The accumulating  information demonstrates that this view must 
be thoroughly reconsidered.  The probability is that repeated injections at more 
widely spaced intervals  of a  selected group  of antigens  will give a  broader, 
firmer,  and more composite coverage. 
DISCUSSION 
The  results  of  the  present  investigation  extend  the  demonstration  that 
antibody responses  to influenza  viruses are persistently oriented by the major 
antigens of strains previously encountered by infection.  The antibody orienta- 
tion of persons of different ages varies owing to recurrent epidemics  caused by 
strains of changing  antigenic  composition. It is now recognized  that  children 
aged 10 or less have been principally exposed to A-prime  strains; that persons 
of military recruit age have been exposed in succession largely to A and A-prime 
viruses,  and that persons over 30 have been exposed seriatim to the swine, A, 
and A-prime  families  of virus. Differences  in the exposures of each age group 
are attributable to coincidence in the time of their childhood and in the periods 
of prevalence of these major antigenic variants of influenza  A (4, 5, 7). 
It has been shown in this and in a preceding study that antibody response 848  INFLUENZA  VIRUS  VACCINES 
to vaccination, like infection,  is dominated by the persistent effects oi "original 
antigenic sin" (9). Vaccination greatly reinforces antibody to strains previously 
encountered but antibody response  to strains encountered for the first time is 
relatively poor. Thus regardless  of whether aqueous monovalent vaccines were 
given repeatedly at short intervals (9), whether monovalent adjuvant vaccines 
were given as a  single  inoculation,  or whether polyvalent vaccines of either 
kind were administered once, high levels  of A-prime  antibodies were induced 
in children,  high levels of A and A-prime antibodies in recruits, and high levels 
of swine and A antibodies in persons over 30. In contrast,  children  remained 
relatively deficient  in swine and A antibodies, recruits in swine antibodies and 
persons  over 30  in  A-prime  antibodies  unless  the  corresponding  strain  was 
given in high  dosage as a  monovalent preparation.  The concordance of these 
findings with the thesis that prior experience predetermines antibody response 
to subsequent exposures, given either by infection or by vaccination, emphasizes 
the validity of that  concept. 
The epidemiologic and immunologic  implications  of this "doctrine of original 
antigenic sin" are extensive. At present, the phenomenon of recurrent epidemics 
of influenza  caused by viruses of varying virulence and of varying antigenic 
composition poses a  unique problem in  the control of communicable disease. 
Several  solutions have been proposed. One presupposes that immunity results 
from highly strain-specific  antibody, and that  the proper course to take is to 
rely, for protection against next year's antigenic variant,  solely upon antibody 
that is produced by vaccines manufactured this year. Such a proposal ignores 
the implications  of the accumulating  data on the relation  between antibody 
and protection in man. A series of studies has shown that resistance to influ- 
enza correlates with the existence  of broadly reacting antibody which affords 
protection  regardless  of minor  antigenic  caprice  in  the prevalent  strain.  To 
recapitulate, dispite highest levels of antibody against the prevailing types of 
virus, the incidence  of influenza  is greatest in childhood;  conversely, the inci- 
dences are  lower  in  the  older segments of the  population  who possess  high 
levels  of antibody against  formerly prevalent  strains  of virus,  but relatively 
low levels of antibody against the prevailing strain (4, 5, 6). Moreover, experi- 
ence has shown that it is logistically unrealistic to expect that sufficient quanti- 
ties of vaccine could be regularly produced from strains  isolated during  one 
respiratory disease season in time for effective use before the next. 
An alternate proposal has been that of using,  as a single inoculation,  poly- 
valent vaccines formulated by inclusion of prototypic strains, to span the major 
antigens that comprise influenza viruses. It was hoped that such a vaccine would 
induce  high  levels  of composite antibody at  all  ages which  would simulate 
that  characteristic of older persons whose experience  with antigenic variants 
of influenza virus is greatest and whose susceptibility is least. Part of the data 
reported in this communication  tested this possibility and  found it wanting 
when the results of a single vaccination were considered.  It seems clear,  then, F.  M.  DAVENPORT  AND A.  V.  HENNESSY  849 
that composite antibody cannot be produced at all ages by current monovalent 
or polyvalent vaccines used as a single dose, owing to the predeterminate effects 
of prior  infections. 
However, the demonstration that vaccination, like infection,  can lay at will 
the foundations for future antibody responses, opens a new and promising vista 
not  circumscribed by age or by commitment  to artificial  though  convenient 
schedules of vaccination. Vaccination has been shown to be capable of initiating 
the processes of accumulating additional antibody dividends upon restimulation 
with  the same or even with antigenically remotely related strains.  Repeated 
vaccinations at  properly spaced intervals with appropriate  viruses would be 
expected to yield a more durable immunity not jeopardized by minor,  though 
at  times seemingly dramatic,  antigenic  changes  in  the  "virus of  the  year." 
Since major antigenic rearrangements yielding new families of A strains occur 
at widely spaced intervals, the antigenic coverage of a polyvalent vaccine can 
be further broadened by the addition of virus antigenically representative of 
each new family, once its status is recognized. The goal for attaining high com- 
posite antibody levels  and  a  higher  degree of immunity  at  all ages,  despite 
differences  in  prior antigenic  experiences  in the population,  seems attainable 
if a  selected group of antigens  is given at  widely spaced intervals.  Progress 
towards this goal encourages future studies designed to determine the mechanics 
of producing a broader, firmer,  more composite coverage of antibody protec- 
tion  against  epidemic  influenza. 
The literature  contains but one study which examines  the hypothesis that 
repeated vaccinations yield a  superior immunity  to epidemic influenza.  The 
data  accumulated  in  this  investigation  of an  outbreak which  occurred  in  a 
boys'  school  suggest  that  greater  resistance  was conferred upon those  indi- 
viduals  who  had  received  two  A-prime  vaccines  at  about  yearly intervals, 
than  on those who had been vaccinated only once with an A-prime  vaccine 
(13).  Obviously, this important lead should be investigated further and trials 
on the efficacy of vaccines of broadest coverage, used in the most efficient man- 
ner, in populations of different age categories must be continued if the optimal 
solution to the problem of vaccination against influenza  is to be found. 
Finally,  it should be pointed out that  the epidemiologic  and  immunologic 
findings  described do not represent phenomena peculiar to influenza.  Rather 
they illustrate a general  principle  applicable to other infections  of man. Data 
which support this conclusion have been observed in rickettsial infections (14), 
in antibody response  to adenovirus vaccines (15), and in infections  caused by 
the arthropod-borne group of animal viruses (16). 
SUMMARY 
The antibody orienting effects of prior infections  with antigenic variants of 
influenza viruses were confirmed by studies with monovalent adjuvant vaccines 
and  with  polyvalent aqueous and  adjuvant  preparations.  In either  case,  the 850  IN~L'UENZA  VIRUS VACCINES 
predominant  antibody response was of a  "booster" type, directed against  the 
major antigens  of strains of original  infection.  It was shown that  vaccination 
with  appropriate  strains,  selected  as  antigenic  prototypes,  could  orient  or 
predetermine subsequent antibody response upon revaccination. Moreover, the 
effects of exposure by vaccination were found to be durable and to constitute 
a  foundation upon which future antibody dividends could be accumulated.  As 
a result, it seems feasible to induce by vaccination a  more lasting  broad com- 
posite  antibody  protection  against  influenza  if appropriate  preparations  and 
schedules are used. 
BIBLIOGRAPHY 
1.  Frost, W. H., Pub. Health Rep.,  U.S.P.H.S.,  1920, 35, 584; Frost,  W. H., and 
Sydenstricker,  E., Pub. Health Rep., U.S.P.H.S., 1919, 34, 491. 
2.  Collins, S. D., Pub. Health Rep., U.S.P.H.S., 1931, 46,1909; 1934, 49, 1; 1944, 59, 
1483. 
3.  Bell,  J.  E.,  unpublished  observations on age incidence  of influenza  A-prime  in 
1953, personal communication. 
4.  Francis, T., Jr., Davenport, F. M., and Hennessy, A. V., Tr. Assn. Am. Physn., 
1953, 66, 231. 
5.  Davenport,  F.  M., Hennessy, A.  V.,  and  Francis,  T.  Jr., J. Exp. Meal., 1953, 
08, 641. 
6.  Francis,  T., Jr., Ann. Int. Med., 1953, 30, 203. 
7.  Hennessy, A.  V.,  Davenport,  F.  M.,  and  Francis,  T.,  Jr., J.  Immunol.,  1955, 
?5, 401. 
8.  Jensen, K. E., and Francis,  T., Jr., J. Exp. Med., 1953, 08, 619. 
9.  Davenport, F. M., and Hennessy, A. V., J. Exp. Med., 1956, 104, 85. 
10.  Committee on Standard Serologic Procedures in Influenza  Studies, J. Im~nunol., 
1950, 65, 347. 
11.  Salk, J. E., Bailey, M. L., and Laurent, A. M., Am. J. ttyg., 1952, 55, 439. 
12.  Hennessy, A. V., and Davenport, F. M., unpublished  data. 
13. Hawkins,  G.  F.  C.,  Hatch,  L. A.,  and  McDonald,  J.  C.,  Brit.  Med.  J.,  1956, 
1200. 
14.  Plotz, H., Science, 1943, 9"/, 20. 
15.  Hilleman,  M. R., StaUones, R. A., Gauld, R. L., Warfield, M. S., and Anderson, 
S. A., Proc. Soc. Exp. Biol. and Med.,  1956, 02, 377. 
16.  Casals, J., Tr. New York Acad. Sc., 1957, 19, 219. 
17.  Meyer,  H.  M.,  Jr.,  Hilleman,  M.  R.,  Miesse,  M.  L.,  Crawford,  I.  P., 
and Bankhead, A. S., Proc. Soc. Exp. Biol. and Med.,  1957, 95, 609. 